Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages

Kosuke Watari, Tomohiro Shibata, Akihiko Kawahara, Ken Ichi Sata, Hiroshi Nabeshima, Ai Shinoda, Hideyuki Abe, Koichi Azuma, Yuichi Murakami, Hiroto Izumi, Takashi Takahashi, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Tumors formed by a highly metastatic human lung cancer cell line are characterized by activated signaling via vascular endothelial growth factor (VEGF)-C through its receptor (VEGFR-3) and aggressive lymph node metastasis. In this study, we examined how these highly metastatic cancers acquired aggressive lymph node metastasis. Compared with their lower metastatic counterparts, the highly metastatic tumors formed by this cell line expressed higher amounts of interleukin (IL)-1α, with similarly augmented expression of IL-1α and IL-1β by tumor stromal cells and of VEGF-A and VEGF-C by tumorassociated macrophages. These tumor-associated macrophages were mainly of the M2 type. Administration of a macrophage-targeting drug suppressed the production of these potent angiogenic and lymphangiogenic factors, resulting in decreased tumor growth, angiogenesis, lymphangiogenesis, and lymph node metastasis. In Matrigel plug assays, the highly metastatic cells formed tumors that were extensively infiltrated by M2-type macrophages and exhibited enhanced angiogenesis and lymphangiogenesis. All of these responses were suppressed by the IL-1 receptor (IL-1R) antagonist anakinra. Thus, the IL-1α-driven inflammatory activation of angiogenesis and lymphangiogenesis seems to provide a highly metastatic tumor microenvironment favorable for lymph node metastasis through cross-talk with macrophages. Accordingly, the IL-1R/M2-type macrophage axis may be a good therapeutic target for patients with this form of lung cancer.

Original languageEnglish
Article numbere99568
JournalPloS one
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 12 2014

Fingerprint

Lymphangiogenesis
Macrophages
interleukin-1
Interleukin-1
metastasis
lymph nodes
Tumors
macrophages
Lymph Nodes
Neoplasm Metastasis
neoplasms
Vascular Endothelial Growth Factor C
vascular endothelial growth factor C
angiogenesis
Neoplasms
lung neoplasms
Lung Neoplasms
Vascular Endothelial Growth Factor Receptor-3
vascular endothelial growth factor receptor-3
Interleukin 1 Receptor Antagonist Protein

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages. / Watari, Kosuke; Shibata, Tomohiro; Kawahara, Akihiko; Sata, Ken Ichi; Nabeshima, Hiroshi; Shinoda, Ai; Abe, Hideyuki; Azuma, Koichi; Murakami, Yuichi; Izumi, Hiroto; Takahashi, Takashi; Kage, Masayoshi; Kuwano, Michihiko; Ono, Mayumi.

In: PloS one, Vol. 9, No. 6, e99568, 12.06.2014.

Research output: Contribution to journalArticle

Watari, K, Shibata, T, Kawahara, A, Sata, KI, Nabeshima, H, Shinoda, A, Abe, H, Azuma, K, Murakami, Y, Izumi, H, Takahashi, T, Kage, M, Kuwano, M & Ono, M 2014, 'Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages', PloS one, vol. 9, no. 6, e99568. https://doi.org/10.1371/journal.pone.0099568
Watari, Kosuke ; Shibata, Tomohiro ; Kawahara, Akihiko ; Sata, Ken Ichi ; Nabeshima, Hiroshi ; Shinoda, Ai ; Abe, Hideyuki ; Azuma, Koichi ; Murakami, Yuichi ; Izumi, Hiroto ; Takahashi, Takashi ; Kage, Masayoshi ; Kuwano, Michihiko ; Ono, Mayumi. / Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages. In: PloS one. 2014 ; Vol. 9, No. 6.
@article{dacbac8d043f460eb5cecab871c0a6ae,
title = "Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages",
abstract = "Tumors formed by a highly metastatic human lung cancer cell line are characterized by activated signaling via vascular endothelial growth factor (VEGF)-C through its receptor (VEGFR-3) and aggressive lymph node metastasis. In this study, we examined how these highly metastatic cancers acquired aggressive lymph node metastasis. Compared with their lower metastatic counterparts, the highly metastatic tumors formed by this cell line expressed higher amounts of interleukin (IL)-1α, with similarly augmented expression of IL-1α and IL-1β by tumor stromal cells and of VEGF-A and VEGF-C by tumorassociated macrophages. These tumor-associated macrophages were mainly of the M2 type. Administration of a macrophage-targeting drug suppressed the production of these potent angiogenic and lymphangiogenic factors, resulting in decreased tumor growth, angiogenesis, lymphangiogenesis, and lymph node metastasis. In Matrigel plug assays, the highly metastatic cells formed tumors that were extensively infiltrated by M2-type macrophages and exhibited enhanced angiogenesis and lymphangiogenesis. All of these responses were suppressed by the IL-1 receptor (IL-1R) antagonist anakinra. Thus, the IL-1α-driven inflammatory activation of angiogenesis and lymphangiogenesis seems to provide a highly metastatic tumor microenvironment favorable for lymph node metastasis through cross-talk with macrophages. Accordingly, the IL-1R/M2-type macrophage axis may be a good therapeutic target for patients with this form of lung cancer.",
author = "Kosuke Watari and Tomohiro Shibata and Akihiko Kawahara and Sata, {Ken Ichi} and Hiroshi Nabeshima and Ai Shinoda and Hideyuki Abe and Koichi Azuma and Yuichi Murakami and Hiroto Izumi and Takashi Takahashi and Masayoshi Kage and Michihiko Kuwano and Mayumi Ono",
year = "2014",
month = "6",
day = "12",
doi = "10.1371/journal.pone.0099568",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages

AU - Watari, Kosuke

AU - Shibata, Tomohiro

AU - Kawahara, Akihiko

AU - Sata, Ken Ichi

AU - Nabeshima, Hiroshi

AU - Shinoda, Ai

AU - Abe, Hideyuki

AU - Azuma, Koichi

AU - Murakami, Yuichi

AU - Izumi, Hiroto

AU - Takahashi, Takashi

AU - Kage, Masayoshi

AU - Kuwano, Michihiko

AU - Ono, Mayumi

PY - 2014/6/12

Y1 - 2014/6/12

N2 - Tumors formed by a highly metastatic human lung cancer cell line are characterized by activated signaling via vascular endothelial growth factor (VEGF)-C through its receptor (VEGFR-3) and aggressive lymph node metastasis. In this study, we examined how these highly metastatic cancers acquired aggressive lymph node metastasis. Compared with their lower metastatic counterparts, the highly metastatic tumors formed by this cell line expressed higher amounts of interleukin (IL)-1α, with similarly augmented expression of IL-1α and IL-1β by tumor stromal cells and of VEGF-A and VEGF-C by tumorassociated macrophages. These tumor-associated macrophages were mainly of the M2 type. Administration of a macrophage-targeting drug suppressed the production of these potent angiogenic and lymphangiogenic factors, resulting in decreased tumor growth, angiogenesis, lymphangiogenesis, and lymph node metastasis. In Matrigel plug assays, the highly metastatic cells formed tumors that were extensively infiltrated by M2-type macrophages and exhibited enhanced angiogenesis and lymphangiogenesis. All of these responses were suppressed by the IL-1 receptor (IL-1R) antagonist anakinra. Thus, the IL-1α-driven inflammatory activation of angiogenesis and lymphangiogenesis seems to provide a highly metastatic tumor microenvironment favorable for lymph node metastasis through cross-talk with macrophages. Accordingly, the IL-1R/M2-type macrophage axis may be a good therapeutic target for patients with this form of lung cancer.

AB - Tumors formed by a highly metastatic human lung cancer cell line are characterized by activated signaling via vascular endothelial growth factor (VEGF)-C through its receptor (VEGFR-3) and aggressive lymph node metastasis. In this study, we examined how these highly metastatic cancers acquired aggressive lymph node metastasis. Compared with their lower metastatic counterparts, the highly metastatic tumors formed by this cell line expressed higher amounts of interleukin (IL)-1α, with similarly augmented expression of IL-1α and IL-1β by tumor stromal cells and of VEGF-A and VEGF-C by tumorassociated macrophages. These tumor-associated macrophages were mainly of the M2 type. Administration of a macrophage-targeting drug suppressed the production of these potent angiogenic and lymphangiogenic factors, resulting in decreased tumor growth, angiogenesis, lymphangiogenesis, and lymph node metastasis. In Matrigel plug assays, the highly metastatic cells formed tumors that were extensively infiltrated by M2-type macrophages and exhibited enhanced angiogenesis and lymphangiogenesis. All of these responses were suppressed by the IL-1 receptor (IL-1R) antagonist anakinra. Thus, the IL-1α-driven inflammatory activation of angiogenesis and lymphangiogenesis seems to provide a highly metastatic tumor microenvironment favorable for lymph node metastasis through cross-talk with macrophages. Accordingly, the IL-1R/M2-type macrophage axis may be a good therapeutic target for patients with this form of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84903398786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903398786&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0099568

DO - 10.1371/journal.pone.0099568

M3 - Article

C2 - 24924428

AN - SCOPUS:84903398786

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e99568

ER -